We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Factor Xa

Factor Xa inhibitors block the serine protease that converts prothrombin to thrombin in blood coagulation. Factor Xa sits where the intrinsic and extrinsic coagulation pathways converge and assembles with factor Va into the prothrombinase complex. Direct inhibitors bind the active site of free and complex-bound factor Xa without a cofactor. Rivaroxaban was described in 2005 as BAY 59-7939, an oral, direct factor Xa inhibitor. The discovery of apixaban from a pyrazolopyridine carboxamide series was reported in 2007. Edoxaban, betrixaban and otamixaban are further direct inhibitors, while RWJ-445167 blocks both factor Xa and thrombin.

Items 51-52 of 52

  • Tanogitran
    Cat. No.
    A74768
    CAS No.
    637328-69-9

    Tanogitran

    Tanogitran is a dual inhibitor that targets Factor Xa and thrombin, exhibiting Ki values of 26 nM and 2.7 nM, respectively. This compound demonstrates significant anticoagulant activity, making it valuable for research in thrombotic diseases and related cardiovascular studies. Researchers can utilize Tanogitran to investigate the mechanisms of coagulation and the potential therapeutic applications in anticoagulation therapy.

    In stock View Details
    25 mg
    $1,275.00
    All 1 sizes
  • Idrabiotaparinux
    Cat. No.
    A77964
    CAS No.
    774531-07-6

    Idrabiotaparinux

    Idrabiotaparinux is a synthetic anticoagulant that acts as a specific, indirect inhibitor of factor Xa. By linking Idraparinux with biotin, this compound enhances its potential for targeted therapeutic applications. Idrabiotaparinux is primarily utilized in research involving blood coagulation pathways and the development of novel anticoagulant therapies.

    View Details

    Out of stock

    All 3 sizes

Items 51-52 of 52

Added to your cart

View Cart Checkout

    Loading...